PMCB (PharmaCyte Biotech) EPS (Basic): $-1.12 (TTM As of Jan. 2026)

What is PharmaCyte Biotech EPS (Basic)?

PharmaCyte Biotech PMCB -0.30% 32 EPS (Basic) is $-1.12 as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's basic earnings per share (Basic EPS) for the three months ended in Jan. 2026 was $-0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2026 was $-1.12.

PharmaCyte Biotech's EPS (Diluted) for the three months ended in Jan. 2026 was $-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 was $-1.12.

PharmaCyte Biotech's EPS without NRI for the three months ended in Jan. 2026 was $-0.34. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2026 was -0.90.

During the past 3 years, the average EPS without NRI Growth Rate was -17.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, PharmaCyte Biotech's highest 3-Year average EPS without NRI Growth Rate was 63.50% per year. The lowest was -33.90% per year. And the median was 24.20% per year.

PharmaCyte Biotech (NAS:PMCB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

PharmaCyte Biotech EPS (Basic) Related Terms

PharmaCyte Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech EPS (Basic) Chart

PharmaCyte Biotech Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Apr25

EPS (Basic)

Get a 7-Day Free Trial

-2.45

-0.27

-0.22

-1.80

3.19

PharmaCyte Biotech Quarterly Data
	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25	Apr25	Jul25	Oct25	Jan26
EPS (Basic)	Get a 7-Day Free Trial															-0.44	1.52	-1.23	-1.24	-0.17

32GF Score

PharmaCyte Biotech Inc PMCB

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

PharmaCyte Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

PharmaCyte Biotech's Basic EPS for the fiscal year that ended in Apr. 2025 is calculated as

Basic EPS (A: Apr. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(30.656	-	1.13)	/	7.330
	=	4.03

PharmaCyte Biotech's Basic EPS for the quarter that ended in Jan. 2026 is calculated as

Basic EPS (Q: Jan. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.747	-	0.098)	/	9.263
	=	0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of $-1.12 mean?

PharmaCyte Biotech (PMCB) has a EPS (Basic) of $-1.12 as of Jan. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on PharmaCyte Biotech and its competitors.

Is PharmaCyte Biotech's EPS (Basic) too high?

PharmaCyte Biotech's current EPS (Basic) is $-1.12. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does PharmaCyte Biotech's EPS (Basic) compare to IMNN and ACXP?

PharmaCyte Biotech's EPS (Basic) of $-1.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current EPS (Basic) is $-1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is PharmaCyte Biotech stock overvalued right now?

PharmaCyte Biotech (PMCB) has a current EPS (Basic) of $-1.12. The current EPS (Basic) is $-1.12. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current EPS (Basic) is $-1.12 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies IMNN ACXP ENVB CURX LABT PBM NCNA CELZ APM BCLI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website https://pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

32GF Score

Get the complete analysis for PMCB

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76

Price

View PMCB Analysis

See EPS (Basic) data for all stocks →